GoAI
Get started
Republic Healthcare Limited logo

Republic Healthcare Limited

8357.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.103

−HK$0.008 · -7.21%

Aug 18, 3:55 PM HKT

8357.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Republic Healthcare Limited, a Singaporean primary healthcare enterprise, furnishes an array of medical services, encompassing consultations, diagnostic examinations, and therapeutic interventions. The company delivers diverse treatment solutions for prevalent health issues, specifically prioritizing sexual health and infectious diseases. Furthermore, it provides remedies for common dermatological ailments and basic medical aesthetics. The organization manages ten clinics in total: nine branded as Dr. Tan & Partners, alongside a single S Aesthetics clinic. Founded in 2010, Republic Healthcare Limited conducts its operations from its headquarters situated in Singapore.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
SG
CEO
Cher Sen Tan
Listed since
Jun 15, 2018
Employees
35

Market position

52-week range

Current HK$0.103

Open
HK$0.103
Previous close
HK$0.111
Volume
515K
5.1× average
Average volume
100.89K
Average daily volume
Market cap
64.27M HKD
Beta
1.33
Market reference 1
50-day average
HK$0.1274
-19.14% below average
200-day average
HK$0.1364
-24.50% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
13.05M SGD
P/E (TTM)
-2.04×
P/B (TTM)
1.31×
P/S (TTM)
1.01×
EV / EBITDA
-7.41×
Earnings yield
-20.54%
Free cash flow yield
-21.58%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-7.69%
Operating margin
-29.71%
Net margin
-40.33%
Return on equity
-31.04%
Return on assets
-18.37%
Return on invested capital
-16.83%

Financial health

Debt / equity
0.43×
Current ratio
3.67×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%38%-5%-49%Gross margin, FY2021: 65.31%Gross margin, FY2022: 63.20%Gross margin, FY2023: 26.24%Gross margin, FY2024: 70.17%Gross margin, FY2025: -0.30%Operating margin, FY2021: -9.79%Operating margin, FY2022: 13.39%Operating margin, FY2023: 18.27%Operating margin, FY2024: 18.42%Operating margin, FY2025: -34.18%Net margin, FY2021: -7.14%Net margin, FY2022: -15.73%Net margin, FY2023: -8.32%Net margin, FY2024: -1.93%Net margin, FY2025: -37.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 65.31%. Gross margin FY2022 63.20%. Gross margin FY2023 26.24%. Gross margin FY2024 70.17%. Gross margin FY2025 -0.30%. Operating margin FY2021 -9.79%. Operating margin FY2022 13.39%. Operating margin FY2023 18.27%. Operating margin FY2024 18.42%. Operating margin FY2025 -34.18%. Net margin FY2021 -7.14%. Net margin FY2022 -15.73%. Net margin FY2023 -8.32%. Net margin FY2024 -1.93%. Net margin FY2025 -37.79%.

Income trends

Revenue

7.84M SGD-15.00%

Operating income

−2.68M SGD−4.38M SGD

Net income

−2.96M SGD-1563.70%
Income trends across reported periods15.67M SGD8.89M SGD2.12M SGD−4.66M SGDRevenue, FY2021: 13.97M SGDRevenue, FY2022: 9.44M SGDRevenue, FY2023: 10.28M SGDRevenue, FY2024: 9.23M SGDRevenue, FY2025: 7.84M SGDOperating income, FY2021: −1.37M SGDOperating income, FY2022: 1.26M SGDOperating income, FY2023: 1.88M SGDOperating income, FY2024: 1.7M SGDOperating income, FY2025: −2.68M SGDNet income, FY2021: −997.93K SGDNet income, FY2022: −1.48M SGDNet income, FY2023: −855.12K SGDNet income, FY2024: −178.16K SGDNet income, FY2025: −2.96M SGDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.97M SGD. Revenue FY2022 9.44M SGD. Revenue FY2023 10.28M SGD. Revenue FY2024 9.23M SGD. Revenue FY2025 7.84M SGD. Operating income FY2021 −1.37M SGD. Operating income FY2022 1.26M SGD. Operating income FY2023 1.88M SGD. Operating income FY2024 1.7M SGD. Operating income FY2025 −2.68M SGD. Net income FY2021 −997.93K SGD. Net income FY2022 −1.48M SGD. Net income FY2023 −855.12K SGD. Net income FY2024 −178.16K SGD. Net income FY2025 −2.96M SGD.
Metric (SGD)FY2025FY2024FY2023FY2022FY2021
Revenue7.84M SGD9.23M SGD10.28M SGD9.44M SGD13.97M SGD
Cost of goods sold7.87M SGD2.75M SGD3.17M SGD3.07M SGD4.24M SGD
Gross profit−23.92K SGD6.48M SGD2.7M SGD5.97M SGD9.13M SGD
Selling, general, and administrative2.66M SGD556.56K SGD819.29K SGD625.71K SGD1.61M SGD
Operating expenses2.66M SGD556.56K SGD7.71M SGD7.31M SGD1.61M SGD
Interest income202.17K SGD210.76K SGD258.26K SGD29.6K SGD11.41K SGD
Interest expense260.38K SGD46.96K SGD53.89K SGD57.13K SGD117.65K SGD
Depreciation and amortization919.88K SGD197.51K SGD803.68K SGD1.01M SGD1.86M SGD
Operating income−2.68M SGD1.7M SGD1.88M SGD1.26M SGD−1.37M SGD
Net income−2.96M SGD−178.16K SGD−855.12K SGD−1.48M SGD−997.93K SGD

Company facts updated Aug 24, 2026.

8357.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 8357.HK

research.disclaimer